Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Desert Gold Report Results from 3,900 Meter Phase 2 Exploration Drill Program (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pfizer Inc PFE

Alternate Symbol(s):  N.PFE

Healthcare
Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the... see more

Recent & Breaking News (NYSE:PFE)

Pfizer Announces Positive Top-Line Results from the First Phase 3 Trial of Investigational Tofacitinib in Adults with Psoriatic Arthritis

Business Wire April 5, 2016

Pfizer and Allergan Issue Statement

Business Wire April 4, 2016

Cancer Metabolism Company Metabomed Completes $18 Million Series A Financing

PR Newswire April 4, 2016

Make A House Call With A Familiar Healthcare ETF

Benzinga.com  April 4, 2016

Pfizer Announces Positive Topline Results from Second Phase 3 Lipid-Lowering Study Evaluating Bococizumab

Business Wire April 1, 2016

Pfizer Inc. (NYSE: PFE) today issued the following statement:

Business Wire March 31, 2016

Pfizer and Allergan Receive Request for Additional Information from Federal Trade Commission Regarding Proposed Combination

Business Wire March 30, 2016

Bristol-Myers Squibb and Pfizer Announce Global Real-World Data Program and Present New Analyses of Eliquis (apixaban) at the American College of Cardiology's 65th Annual Scientific Session

Business Wire March 30, 2016

The Stocks That Moved The S&P, Dow And Nasdaq Today

Benzinga.com  March 28, 2016

Pfizer Announces European Medicines Agency Accepted for Review Its Marketing Authorization Application for XELJANZ® (Tofacitinib Citrate) for the Treatment of Moderate to Severe Rheumatoid Arthritis

Business Wire March 23, 2016

Pfizer Invites Public to View and Listen to Webcast of May 3 Conference Call with Analysts

Business Wire March 22, 2016

Pfizer Joins The Human Vaccines Project To Help Decode The Immune System

Business Wire March 22, 2016

Pfizer Announces Oral Tofacitinib, an Investigational JAK Inhibitor, Meets Primary and Key Secondary Endpoints in Two Pivotal Phase 3 Ulcerative Colitis Trials

Business Wire March 18, 2016

Pfizer to Present New Data on Investigational Tofacitinib in Inflammatory Bowel Disease at the 11th Congress of ECCO

Business Wire March 16, 2016

Pfizer Celebrates a Year of Achievements in 2015 Annual Review

Business Wire March 15, 2016

XALKORI® (crizotinib) Approved by U.S. FDA for the Treatment of Patients with ROS1-Positive Metastatic Non-Small Cell Lung Cancer

Business Wire March 11, 2016

New Survey Reveals Many Living with Symptoms of Diabetic Nerve Pain Are Undiagnosed Despite Severe and Constant Pain

Business Wire March 9, 2016

Pfizer Commences $5 Billion Accelerated Share Repurchase

Business Wire March 9, 2016

Pfizer Announces Publication of Study Results of BeneFIX® Coagulation Factor IX (Recombinant) Once-Weekly Prophylaxis for Hemophilia B

Business Wire March 8, 2016

The Other Sector ETF Player

Benzinga.com  March 7, 2016